-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the author's statistics, as of March 1, 2022, there have been 250 listed companies that have disclosed their 2021 performance reports, and more than half of them are reporting good news
.
As far as the industries that profitable companies belong to, pharmaceutical biology and chemical industry have performed well
.
Judging from the growth rate of net profit, many companies have increased by more than 10 times
.
Among them, the net profit of Nord shares in 2021 will increase by 7409.
91% year-on-year, and the growth rate of Thermal View Biotechnology will be as high as 1856.
81%.
In addition, the net profit of Eastcom shares will also increase by more than 1000%
.
On the evening of February 27, Rejing Bio announced that its net profit in 2021 would surge by nearly 19 times
.
Regarding the reasons for the sharp increase in performance, Rejing Bio said that it was mainly affected by the epidemic
.
At the beginning of 2021, the two products developed by the company, the new antigen detection kit (anterior nasal cavity) and the new antigen detection kit (saliva), were certified by the German Federal Institute for Drugs and Medical Devices (BfArM) for free home testing earlier.
It has been applied locally in Germany, and the company's foreign trade orders have exploded in the first half of the year
.
In the second half of the year, the emerging antigen self-test products developed by the company have successively passed the self-test registration/filing of major economies such as the European Union CE, the British MHRA, and the French ANSM, and the demand for antigen test products in Europe, Southeast Asia and other countries and regions has increased significantly.
The Company achieved substantial growth in revenue from overseas antigen testing products
.
After the company's performance report was released, it quickly attracted the attention of the pharmaceutical industry, and its stock price also rose sharply
.
As of the close on February 28, Hot View Bio reported an increase of 15.
14% to 174.
11 yuan per share
.
It is understood that the stock price trend of Rejing Bio in the past two years can be described as a roller coaster
.
Since April 12, 2021, the company has disclosed the announcement that the net profit attributable to the parent has increased by more than 1,100 times in the first quarter of that year.
As high as 237 yuan, the periodic increase of more than 370%, the performance can be described as dazzling
.
Subsequently, the company's stock price began to decline.
After the announcement of a substantial pre-increase in net profit on January 7, 2022, the stock price began to soar again, but it began to fall again shortly after
.
Now, with the release of the company's earnings report, the stock price has risen again
.
According to the data, Rejing Bio is mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments.
The main products are in vitro diagnostic reagents and instruments
.
From the perspective of the entire in vitro diagnostic industry, China's in vitro diagnostic industry has continued to grow in recent years.
The market size in 2020 will reach 89 billion yuan.
Driven by factors such as an aging population, accelerated technological updates, and favorable policy support, the market size is expected to remain further expand
.
However, what needs to be seen is that the industry has grown rapidly since 2020, mainly due to the impact of the epidemic
.
Some analysts believe that with the normalization of domestic epidemic prevention and control, the intensified competition in the testing industry, and the advancement of the centralized procurement policy, it is expected that the domestic testing market demand will decline, and at the same time, "volume and price decline" will become a trend
.
This also means that the future performance of relevant testing companies may be uncertain
.
In addition to Rejing Bio, among the pharmaceutical and biological companies that have disclosed their performance reports, Sunshine Guojian's net profit has also doubled
.
In 2021, the company will realize a net profit of 18.
1212 million yuan attributable to shareholders of listed companies, a year-on-year increase of 108.
33%
.
The main reason for the change in performance is that the company announced a significant increase in sales after the price reduction of Yisaipu since October 2020, and the sales revenue also increased accordingly; at the same time, the company adjusted its sales strategy accordingly, and the sales expenses were greatly reduced
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
As far as the industries that profitable companies belong to, pharmaceutical biology and chemical industry have performed well
.
Judging from the growth rate of net profit, many companies have increased by more than 10 times
.
Among them, the net profit of Nord shares in 2021 will increase by 7409.
91% year-on-year, and the growth rate of Thermal View Biotechnology will be as high as 1856.
81%.
In addition, the net profit of Eastcom shares will also increase by more than 1000%
.
On the evening of February 27, Rejing Bio announced that its net profit in 2021 would surge by nearly 19 times
.
Regarding the reasons for the sharp increase in performance, Rejing Bio said that it was mainly affected by the epidemic
.
At the beginning of 2021, the two products developed by the company, the new antigen detection kit (anterior nasal cavity) and the new antigen detection kit (saliva), were certified by the German Federal Institute for Drugs and Medical Devices (BfArM) for free home testing earlier.
It has been applied locally in Germany, and the company's foreign trade orders have exploded in the first half of the year
.
In the second half of the year, the emerging antigen self-test products developed by the company have successively passed the self-test registration/filing of major economies such as the European Union CE, the British MHRA, and the French ANSM, and the demand for antigen test products in Europe, Southeast Asia and other countries and regions has increased significantly.
The Company achieved substantial growth in revenue from overseas antigen testing products
.
After the company's performance report was released, it quickly attracted the attention of the pharmaceutical industry, and its stock price also rose sharply
.
As of the close on February 28, Hot View Bio reported an increase of 15.
14% to 174.
11 yuan per share
.
It is understood that the stock price trend of Rejing Bio in the past two years can be described as a roller coaster
.
Since April 12, 2021, the company has disclosed the announcement that the net profit attributable to the parent has increased by more than 1,100 times in the first quarter of that year.
As high as 237 yuan, the periodic increase of more than 370%, the performance can be described as dazzling
.
Subsequently, the company's stock price began to decline.
After the announcement of a substantial pre-increase in net profit on January 7, 2022, the stock price began to soar again, but it began to fall again shortly after
.
Now, with the release of the company's earnings report, the stock price has risen again
.
According to the data, Rejing Bio is mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments.
The main products are in vitro diagnostic reagents and instruments
.
From the perspective of the entire in vitro diagnostic industry, China's in vitro diagnostic industry has continued to grow in recent years.
The market size in 2020 will reach 89 billion yuan.
Driven by factors such as an aging population, accelerated technological updates, and favorable policy support, the market size is expected to remain further expand
.
However, what needs to be seen is that the industry has grown rapidly since 2020, mainly due to the impact of the epidemic
.
Some analysts believe that with the normalization of domestic epidemic prevention and control, the intensified competition in the testing industry, and the advancement of the centralized procurement policy, it is expected that the domestic testing market demand will decline, and at the same time, "volume and price decline" will become a trend
.
This also means that the future performance of relevant testing companies may be uncertain
.
In addition to Rejing Bio, among the pharmaceutical and biological companies that have disclosed their performance reports, Sunshine Guojian's net profit has also doubled
.
In 2021, the company will realize a net profit of 18.
1212 million yuan attributable to shareholders of listed companies, a year-on-year increase of 108.
33%
.
The main reason for the change in performance is that the company announced a significant increase in sales after the price reduction of Yisaipu since October 2020, and the sales revenue also increased accordingly; at the same time, the company adjusted its sales strategy accordingly, and the sales expenses were greatly reduced
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
